OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Device Related Thrombosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 968 reports · 51 co-occurring drugs

As of the last recalculation, Device Related Thrombosis appears in 968 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 66.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Teduglutide4066.566.7
Pegaspargase2341.441.4
Epoprostenol2440.440.5
Blinatumomab1837.837.8
Exemestane3435.335.4
Heparin Sodium2031.932.0
Cannabidiol3028.428.5
Fluorouracil Cream, 0.5%8626.526.5
Emicizumab1526.526.5
Fluorouracil8626.126.2
Ivacaftor924.624.6
Vincristine Sulfate2921.921.9
Tobramycin Solution1119.919.9
Tobramycin Sulfate1119.319.3
Olmesartan Medoxomil3119.119.1
Letrozole Tablets4119.119.1
Filgrastim2917.117.1
Everolimus3515.315.3
Oxaliplatin4914.914.9
Letrozole4114.914.9
Carfilzomib1914.714.7
Obinutuzumab1114.514.5
Cytarabine3914.514.5
Acetaminophen And Codeine814.214.2
Doxorubicin5413.713.7
Doxorubicin Hydrochloride2013.413.4
Paclitaxel (Aibumin-Bound)4813.213.2
Cyclophosphamide Injection, Solution9713.013.0
Cyclophosphamide9713.013.0
Cyclophosphamide For Injection9713.013.0
Capecitabine5212.912.9
Irinotecan Hydrochloride711.811.8
Tobramycin1311.811.8
Alteplase811.511.5
Carboplatin6411.511.5
Panitumumab811.111.1
Paclitaxel4810.910.9
Treprostinil5910.710.7
Granisetron510.310.3
Lumacaftor And Ivacaftor410.110.1
Macitentan319.99.9
Bevacizumab539.79.7
Polatuzumab Vedotin48.88.8
Axicabtagene Ciloleucel48.78.8
Riociguat128.08.0
Ravulizumab58.08.0
Dornase Alfa66.66.6
Atezolizumab116.16.2
Daratumumab116.06.0
Durvalumab55.35.3
Pomalidomide153.23.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.